News Update

May 01, 2002
Pharmaceutical Executive
Because of the European Union's country-by-country drug price controls, enterprising wholesalers often buy prescription drugs in nations that keep prices low and resell them in countries that allow higher prices. Sanofi-Synthelabo's Plavix costs $55 in France but is resold for $79 in England. That long-standing practice, known as parallel trade, costs the pharma industry an estimated $3 billion in lost profits each year.
May 01, 2002
Pharmaceutical Executive
A flood of counterfeit medications into the Nigerian market is causing great concern among the nation's regulatory authorities, according to a British Medical Journal report. Many fakes may contain a small amount of the active ingredient but not enough to make them therapeutically useful. Under-strength antibiotics represent a significant public health problem, as the inadvertent administration of them can lead to bacterial resistance.
May 01, 2002
Pharmaceutical Executive
African-American physicians regard direct-to-consumer advertising of prescription medicines as one way to educate minority patients about needed treatment and healthcare options, according to a survey conducted by the National Medical Association (NMA). Almost all of the 900 physicians answering the questionnaire reported that DTC advertising has prompted patients to ask questions, and one-third acknowledged that they feel additional pressure to justify their prescribing decisions. But almost half (48 percent) said that such promotion increased communications between physicians and patients.
May 01, 2002
Pharmaceutical Executive
The National Institute of Health Care Management made headlines with its report on double-digit increases (17 percent) in retail spending on medicines in 2001. The total reached $155 billion last year, almost double the $80 billion spent in 1997, according to the study, "Another Year of Escalating Costs." PhRMA president Alan Holmer said the increase is a good thing, signifying that more people who need medicines for chronic conditions are being treated and thereby avoiding more expensive medical procedures.
Apr 01, 2002
Pharmaceutical Executive
Brussels, Belgium-Tackling communicable diseases such as malaria and tuberculosis and making pregnancy and childbirth safer are priorities for the restructured Afghan health ministry, according to World Health Organization officials.
Apr 01, 2002
Pharmaceutical Executive
As proposals proliferate to establish a Medicare pharmacy benefit, the cost estimates continue to soar. The White House began in February by proposing to spend a measly $190 billion over ten years.
Apr 01, 2002
Pharmaceutical Executive
A new report by Médecins Sans Frontières (MSF) scotches the myth that the most effective forms of malaria treatment are too expensive for East African countries.
Apr 01, 2002
Pharmaceutical Executive
Eli Lilly recently joined the growing list of pharma companies offering discount card programs for Medicare beneficiaries in an effort to "do something now" to help low-income seniors afford medicines. Although Lilly chairman Sidney Taurel voiced support for a broader drug benefit for the elderly-as do his pharma colleagues-he described the LillyAnswers program as "quick relief" while the Medicare-reform debate continues.
Apr 01, 2002
Pharmaceutical Executive
Capetown-In March, ruling on a case initiated by the Treatment Action Campaign, Save Our Babies, and the Children's Rights Centre, Judge Chris Botha ordered the South African government to provide the anti-retroviral nevirapine to all HIV-positive pregnant women.
Apr 01, 2002
Pharmaceutical Executive
GSK Faces Bribe Charges, Changing of the Guard
native1_300x100
lorem ipsum